Efficacy and safety of propofol tenofovir in the treatment of chronic hepatitis B complicated with nonalcoholic fatty liver disease

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900023153

Enrollment

Unknown

Registered

2019-05-14

Start date

2019-08-01

Completion date

Unknown

Last updated

2019-05-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic viral hepatitis B with nonalcoholic fatty liver disease

Interventions

CHB with NAFLD group + CHB without NAFLD group:Propofol Tenofovir

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: (1) Non-alcoholic fatty liver disease should meet the diagnostic criteria of NAFLD, but HBV infection must be complicated, including: 1 no history of drinking or alcohol-converted amount of alcohol in males < 140 g per week, females < 70 g per week; 2 exclusion of drug-induced liver disease, total parenteral nutrition, hepatolenticular degeneration and other specific diseases that can lead to fatty liver disease; 3 hepatic imaging manifestations conform to the diagnosis of diffuse fatty liver disease and There is no other reason to explain it. (2) Patients aged 18-60 years; (3) Guidelines for the prevention and treatment of chronic hepatitis B in 2015, in line with the indications for antiviral therapy; (4) Willing to sign informed consent.

Exclusion criteria

Exclusion criteria: (1) Complicated with other viral hepatitis, alcoholic fatty liver and metabolic liver diseases; (2) TAF use contraindication; (3) Complicated with decompensated liver cirrhosis, advanced liver cancer and other decompensated liver diseases; (4) Pregnant and lactating women; (5) Osteopathy: Long-term use of steroids or other drugs that exacerbate bone mineral density changes Fragile osteopathy and osteoporosis (6) Renal function changes: EGFR<60 ml/min/1,73 M2 Proteinuria greater than 30 mg/24 hours or moderate proteinuria detected by test paper Low blood phosphorus level (less than 2.5mg/dl) Hemodialysis (7) Researchers believe that other situations are not suitable for inclusion.

Design outcomes

Primary

Measure	Time frame
HBV DNAInhibition rate;renal function;Osteoporosis;	—

Secondary

Measure	Time frame
ALT recurrence rate;Liver hardness;	—

Countries

China

Contacts

Public ContactJinyu Xia

Fifth Affiliated Hospital of Sun Yat-sen University

xiajinyu@mail.sysu.edu.cn+86 13823078064

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026